Importantly, our findings revealed that the concomitant overexpression of SDHA and LRPPRC could be considered as novel biomarkers for identifying tumors that rely on high OXPHOS metabolism, offering a potential avenue for tailoring personalized cancer treatments. Here, LRPPRC is linked to cancer.